Stephens Reaffirms “Overweight” Rating for Actinium Pharmaceuticals (NYSE:ATNM)

Actinium Pharmaceuticals (NYSE:ATNM)‘s stock had its “overweight” rating reiterated by stock analysts at Stephens in a research report issued on Tuesday,Benzinga reports. They presently have a $5.00 price objective on the stock. Stephens’ target price would suggest a potential upside of 405.05% from the stock’s previous close.

Actinium Pharmaceuticals Stock Down 0.5%

Shares of NYSE ATNM opened at $0.99 on Tuesday. Actinium Pharmaceuticals has a 52 week low of $0.95 and a 52 week high of $1.95. The firm’s fifty day moving average is $1.14 and its 200 day moving average is $1.35. The company has a market cap of $30.88 million, a price-to-earnings ratio of -0.71 and a beta of -0.31.

Institutional Trading of Actinium Pharmaceuticals

Institutional investors have recently modified their holdings of the company. Bank of America Corp DE grew its stake in shares of Actinium Pharmaceuticals by 76.6% in the fourth quarter. Bank of America Corp DE now owns 78,767 shares of the company’s stock worth $99,000 after purchasing an additional 34,176 shares during the last quarter. AQR Capital Management LLC raised its position in Actinium Pharmaceuticals by 278.6% during the 1st quarter. AQR Capital Management LLC now owns 63,249 shares of the company’s stock valued at $102,000 after purchasing an additional 46,545 shares during the last quarter. Marshall Wace LLP purchased a new stake in Actinium Pharmaceuticals in the 2nd quarter worth approximately $137,000. Qube Research & Technologies Ltd purchased a new stake in Actinium Pharmaceuticals in the 2nd quarter worth approximately $70,000. Finally, Jane Street Group LLC bought a new stake in shares of Actinium Pharmaceuticals in the 2nd quarter worth approximately $306,000. 27.50% of the stock is currently owned by hedge funds and other institutional investors.

Actinium Pharmaceuticals Company Profile

Actinium Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on the development of targeted radiopharmaceutical therapies for patients with hematologic malignancies. The company’s proprietary technology platform combines monoclonal antibodies with radioisotopes to deliver highly potent, cell‐killing radiation directly to cancer cells while sparing healthy tissues. Actinium’s lead product candidate, Iomab‐B, is being evaluated as a conditioning regimen for older patients with acute myeloid leukemia (AML) who are ineligible for standard bone marrow transplants.

In addition to Iomab‐B, Actinium’s pipeline includes Actimab‐A, an anti‐CD33 antibody labeled with the radioisotope bismuth‐213 for the treatment of relapsed or refractory AML.